FRANKFURT, GERMANY - CureVac, the German biotech firm at the center of an argument over alleged U.S. attempts to gain access to an experimental coronavirus vaccine it is developing, denied Tuesday it had received U.S. offers for the company or its assets.
European Union leaders said they would discuss Tuesday via videoconference how to prevent hostile U.S. takeovers of EU-based research firms at the forefront of developing drugs and vaccines against the coronavirus, officials said.
Media reports that Washington had tried to gain access to the vaccine stirred a political backlash in Germany, with economy minister Peter Altmaier and interior minister Horst Seehofer voicing support for keeping CureVac German.
The U.S. overture was first reported by Welt am Sonntag and confirmed to Reuters by German government sources. However, the U.S. ambassador to Germany, Richard Grenell, said on Twitter that the German newspaper report was wrong.
Köhnə versiyamızdan xəbərləri izlə